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The activity of the serine/threonine kinase c-Raf (Raf)
is inhibited by increased intracellular cAMP. This is
believed to require phosphorylation with the cAMP-de-
pendent protein kinase (PKA), although the mechanism
by which PKA inhibits Raf is controversial. We investi-
gated the requirement for PKA phosphorylation using
Raf mutants expressed in HEK293 or NIH 3T3 cells.
Phosphopeptide mapping of 32P-labeled Raf (WT) or a
mutant lacking a putative PKA phosphorylation site
(serine to alanine, S43A) confirmed that serine 43 (Ser43)
was the major cAMP (forskolin)-stimulated phosphoryl-
ation site in vivo. Interestingly, the EGF-stimulated Raf
kinase activity of the S43A mutant was inhibited by
forskolin equivalently to that of the WT Raf. Forskolin
also inhibited the activation of an N-terminal deletion
mutant D5–50 Raf completely lacking this phosphoryla-
tion site. Although WT Raf was phosphorylated by PKA,
phosphorylation did not inhibit Raf catalytic activity in
vitro, nor did forskolin treatment inhibit the activity of
an N-terminally truncated Raf protein (Raf 22W) or a
full-length Raf protein (Raf-CAAX) expressed in NIH 3T3
cells. In contrast, forskolin inhibited the EGF-depend-
ent activation of a Raf isoform (B-Raf), lacking an anal-
ogous phosphorylation site to Ser43. Thus, these results
demonstrate that PKA exerts its inhibitory effects inde-
pendently of direct Raf phosphorylation and suggests
instead that PKA prevents an event required for the
EGF-dependent activation of Raf.
The mitogen-activated protein kinase (MAPK)1 cascade is a
conserved phosphorylation pathway involved in the transduc-
tion of growth and differentiation signals in both simple and
complex organisms (reviewed in Ref. 1). In the now established
paradigm, peptide growth factors bind to their receptor tyro-
sine kinases, increasing intracellular protein tyrosine phospho-
rylation and stimulating the exchange of GDP for GTP in small
GTP-binding proteins such as Ras (reviewed in Ref. 2). Raf, a
74-kDa serine/threonine kinase, binds to Ras-GTP at the
plasma membrane, thus providing an integral link between the
receptor-mediated events and activation of the MAPK cascade
(3, 4). The activation of Raf is a complex process involving
membrane recruitment, interactions with the proteins 14-3-3
(5), hsp90 (6), and regulation by Src family tyrosine kinases (7),
protein kinase Ca (8), the kinase suppressor of Ras (Ksr) (9),
and most recently p21-activated kinase (PAK) (10) (for reviews,
see Refs. 11 and 12). In addition, Raf activation may also be
mediated by cytoskeletal factors that lead to the enhancement
Raf but not Ras activity in cells (13). Once activated, Raf
phosphorylates and activates MAPK kinase (14, 15) (MAPKK
or MEK (16)), which in turn phosphorylates MAPK (17, 18) as
part of the sequence of events leading to the activation of
MAPK in mammalian cells (1).
Compounds that increase intracellular cAMP (e.g. glucagon,
epinephrine, prostaglandins) are known to oppose the activa-
tion of the MAPK cascade in many cell types (for a review, see
Ref. 19). This inhibitory effect requires activation of the cAMP-
dependent protein kinase (PKA) (20), although the actual
mechanism by which this is achieved is controversial. Neither
MAPK kinase nor MAPK are phosphorylated by PKA, and
elevating cAMP does not inhibit receptor tyrosine phosphoryl-
ation, phosphatidylinositol turnover, or activation of Ras-GTP
in response to growth factor treatment (19–23). Instead, con-
siderable effort has focused on the serine/threonine kinase
c-Raf-1 (c-Raf) as the target of inhibition, and c-Raf is consis-
tently inhibited in cells after elevation of cAMP. PKA phospho-
rylates substrates containing tandem basic residues upstream
of a phosphorylatable serine or threonine residue (24, 25), and
c-Raf contains a consensus PKA phosphorylation site at serine
43 (RRAS). Serine 43 has been shown to be phosphorylated in
vivo (22, 26), and although the phosphorylation of this amino
acid does not inhibit the catalytic activity of c-Raf (26), it has
been proposed to disrupt normal Ras/Raf association and c-Raf
activation in vivo (22).
Although this model has been widely accepted, the require-
ment for Ser43 phosphorylation has not been directly tested in
vivo, and alternative models have been proposed. The studies of
Kolch and co-workers (27, 28) suggest that the catalytic activity
of c-Raf is directly inhibited by PKA and propose that phospho-
rylation of Ser621 within the catalytic domain of c-Raf is respon-
sible for this effect. However, this hypothesis has been difficult
to test because the autophosphorylation of Ser621 is required
for Raf kinase activity (5), and increased phosphorylation of
Ser621 in response to cAMP has not been demonstrated.
The effect of cAMP on other isoforms of c-Raf has also been
examined. However, in comparison with the consistent inhibi-
tion found with c-Raf, the influence of cAMP on the related
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enzyme B-Raf is more complex. There are examples of inhibi-
tion (29, 30), activation (31), or no effect (32), of cAMP on
B-RAF which may depend on the stimulus, the cell type, or the
culture conditions (33, 34). B-Raf lacks an analogous Ser43
phosphorylation as found in c-Raf but does contain a similar
Ser621 phosphorylation site (35). In contrast to some of the
studies on c-Raf (27, 28), B-Raf does not appear to be directly
inhibited by PKA phosphorylation (32). The third Raf isoform,
A-Raf, is not widely expressed in cells and may be resistant to
the inhibitory effects of cAMP (36).
The fact that no single consensus model appears sufficient to
explain the regulation of Raf (c- or B-Raf) has led to the search
for other targets. The Rap proteins (Rap 1a/b) are phosphoryl-
ated by PKA (37), can bind Raf, and block Ras signaling when
overexpressed in cells (38, 39). Thus, these proteins were orig-
inally proposed to be candidates for mediating the cAMP-de-
pendent inhibition of Raf. However, recent studies suggest that
Rap is not required for inhibition of MAPK signaling (40) and
demonstrate that Rap 1b is activated by cAMP (41). This ap-
pears to occur independently of the action of PKA (42) and may
play a mitogenic role (43) through the cAMP-dependent acti-
vation of B-Raf (31).
Hence, the studies described herein were designed to resolve
some of the remaining questions concerning Raf regulation by
cAMP. Importantly, we find that deletion of the major PKA
phosphorylation site (Ser43) does not impede the cAMP-de-
pendent inhibition of Raf in vivo. Furthermore, we find no
evidence for a cAMP-stimulated increase in the phosphoryla-
tion of Ser621 in vivo or a direct inhibitory effect of PKA on Raf
either in vitro or on constitutively activated Raf kinases (Raf
22W, Raf-CAAX) expressed in vivo. Finally, examination of an
alternative isoform (B-Raf) lacking an analogous Ser43 phos-
phorylation site demonstrated that forskolin prevented the
EGF-dependent activation of this enzyme, consistent with PKA
interrupting an event required for Raf activation rather than
inhibiting Raf itself.
EXPERIMENTAL PROCEDURES
Materials—EGF, LipofectAMINE, and Opti-MEM I reduced serum
media were purchased from Life Technologies, Inc. Forskolin was pur-
chased from Biomol (Plymouth Meeting, PA) and dissolved in Me2SO.
[g-32P]ATP was obtained from NEN Life Science Products.
[32P]Orthophosphate was purchased from ICN (Costa Mesa, CA). Pro-
tein A-agarose beads were purchased from Bio-Rad and washed three
times with PBS prior to use. The purified active catalytic subunit of
PKA was purchased from New England Biolabs. Anti-FLAG M2 anti-
body was purchased from Eastman Kodak Co. Anti-c-Raf-1 was pur-
chased from Transduction Laboratories (Lexington, KY) for use in im-
munoblots. In other experiments, antibodies specific for A-Raf (C-20),
B-Raf (C-19), and c-Raf (C-20) were obtained from Santa Cruz Biotech-
nology, Inc. (Santa Cruz, CA). Anti-HA antibody was purchased from
Berkeley Antibody Company (Berkeley, CA) for use in immunoprecipi-
tations. FLAG epitope-tagged Raf and S43A Raf (pCDNA3) and the
baculovirus expressing Raf and Src were provided by Dr. Deborah
Morrison (NCI, National Institutes of Health, Frederick MD). The
FLAG epitope (DYKDDDDK) was added by deleting the last eight
amino acids of Raf and replacing them with the FLAG tag. HA epitope-
tagged Raf, Raf-CAAX (pCGN), NIH 3T3 cells expressing Raf 22W, and
recombinant MEK and Erk-2 were provided by Dr. Channing Der
(University of North Carolina, Chapel Hill, NC). The QuikChange site-
directed mutagenesis kit was obtained from Stratagene (La Jolla, CA).
ECL reagents were purchased from NEN Life Science Products. Immo-
bilon polyvinylidene difluoride membrane was purchased from Milli-
pore Corp.
Cell Cultures—Human embryonic kidney cells (HEK 293) were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal
bovine serum (FBS) and penicillin/streptomycin on 60- or 150-mm
plates in a humidified, 5% CO2 atmosphere. 24 h prior to the experi-
ments, the medium was removed and replaced with DMEM with 0.1%
FBS and penicillin/streptomycin. The rat liver epithelial cells (GN4)
were grown and harvested as described earlier (44). Sf9 cells were
grown and infected with baculovirus as described in Ref. 7.
Transient Transfection of Cells—Transient transfection of the cells
was performed using LipofectAMINE according to the manufacturer’s
suggested protocol (Life Technologies, Inc.). Briefly, 2 mg of plasmid and
2 mg of carrier DNA, usually empty pCDNA3 were transfected with 8 ml
of LipofectAMINE in serum-free DMEM into cells grown on 60-mm cell
culture plates for 48 h. For transient transfection of 100-mm plates, 4
mg of plasmid and carrier DNA was used. For transient transfection of
150-mm plates, 8 mg of plasmid and 8 mg of carrier DNA in 100 ml of
LipofectAMINE were used. Cells grown to 50% confluence were washed
once with 13 PBS and once with serum-free DMEM. DNA/Lipo-
fectAMINE/DMEM was placed on cells and incubated for 5 h at 37 °C.
DMEM with 20% FBS and penicillin/streptomycin was then added to
the plates and incubated for an additional 24 h. Cells were serum-
starved for 24 h with DMEM with 0.1% FBS and penicillin/streptomy-
cin prior to the experiment.
Cell Lysate Preparation—Following drug treatment, cells were
washed twice with cold PBS and harvested in 1 ml of ice-cold lysis
buffer (20 mM Tris, pH 7.5, 1% Triton, 10% (v/v) glycerol, 137 mM NaCl,
2 mM EDTA, 5 mg/ml leupeptin, 10 nM calyculin A, 250 mM phenylmeth-
ylsulfonyl fluoride, and 150 mM sodium orthovanadate). The cell lysates
were centrifuged at 15,000 rpm for 10 min, and the resultant superna-
tants were transferred to a new microcentrifuge tube. Protein concen-
tration of the cell lysates was determined by Coomassie protein assay
reagent (Pierce). The same procedure was used to isolate Raf from
baculovirus.
Measurement of c-Raf-1 Kinase Activity—2 mg of anti-FLAG antibody
was added to 1 mg of clarified cell lysate. Samples were rotated for 1.5 h
at 4 °C. 20 ml of protein A beads in PBS were then added to the
supernatants and rotated end over end for an additional 40 min at 4 °C.
The immune complexes were placed on ice and washed twice in cold
immunoprecipitation buffer and twice in cold PBS. The remaining
supernatant was removed from the protein A beads with a Hamilton
syringe. Raf activity was measured by using a coupled enzyme assay
containing MEK and extracellular signal-regulated kinase-2 (Erk-2)
and quantitating the incorporation of radioactive phosphate into myelin
basic protein as described below. The immunocomplexes were incu-
bated in 10 ml of a cold ATP mixture (20 mM Hepes, pH 7.3, 10 mM
b-glycerophosphate, 1.33 mM EGTA, 0.15 mM Na3VO4, 0.5 mM dithio-
threitol, 10 mM MgCl2, 0.1 mM ATP, and 0.1 mg/ml bovine serum
albumin) and 0.5 mg of recombinant MEK for 10 min at 30 °C. 1.25 mg
of recombinant extracellular signal-regulated kinase-2 was added to the
samples and incubated for an additional 10 min at 30 °C. Finally, 20 ml
of a radioactive ATP mixture (2 mCi of [g-32P]ATP, 10 mg of myelin basic
protein, 20 mM Hepes, pH 7.3, 10 mM b-glycerophosphate, 1.33 mM
EGTA, 0.15 mM Na3VO4, 0.5 mM dithiothreitol, 10 mM MgCl2, 0.1 mg/ml
bovine serum albumin) was added and incubated for 10 min at 30 °C.
The reaction was terminated with the addition of 20 ml of 100 mM
EDTA. Samples were centrifuged at 12,000 3 g for 1 min to pellet the
beads, and 40 ml of the reaction mixture was spotted onto squares (2 3
2 cm) of P-81 paper. P-81 papers were washed in 75 mM phosphoric acid
five times (5–10 min), washed once briefly in 100% ethanol, and air-
dried. The P-81 papers were counted in a Beckman LS 6500 scintillation
counter in 0.5 ml of Scintisafe (Fisher) scintillation fluid. Using these
conditions, the assay of Raf activity was determined to be linear with
respect to time and Raf concentration.
Phosphopeptide Mapping of c-Raf-1 Kinase—293 cells were tran-
siently transfected with WT or S43A Raf-FLAG and grown to conflu-
ence in 150-mm plates. Prior to the addition of [32P]orthophosphate,
cells were incubated in 12 ml of phosphate-free, 0.1% FBS DMEM for 30
min. 3.0 mCi of [32P]orthophosphate was then added to each plate for
2.5 h. Following labeling, plates were treated with 25 mM forskolin in
Me2SO for 15 min or left untreated. Cells were harvested and Raf-
FLAG was immunoprecipitated with 10 mg of FLAG antibody and 50 ml
of protein A beads in PBS. Beads were washed as above. Raf-FLAG was
removed from the beads by heating twice in 100 ml of sample buffer.
Phosphorylated Raf-FLAG was applied to 10% SDS-PAGE, and the gel
was fixed in a 25% isopropyl alcohol, 10% acetic acid solution. The gel
was then washed three times in water and once in 0.1 M NH4HCO3, pH
8.5. The gel was dried, and autoradiography was performed to identify
radioactive bands. The band corresponding to Raf (74 kDa) was excised
from the gel and swelled in a solution containing 100 ml of 0.1 M
NH4HCO3, pH 8.5, and 20 mg of trypsin and incubated at 37 °C over-
night. The supernatant was removed and used for two-dimensional
phosphopeptide mapping as described previously (45). Peptides
were resolved electrophoretically (100 V/14 min) using pH 1.9 buffer
in one dimension and chromatographically with isobutyric acid
buffer in the second dimension. Autoradiography was performed to
visualize the radioactive peptides. In other experiments, synthetic
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peptides containing the Ser43 (GYQRRASDDGKLTD) or Ser621
(LPKINRSASEPSLHRAA) phosphorylation sites were synthesized by
Dr. David G. Klapper (University of North Carolina, Chapel Hill).
These peptides were phosphorylated with the purified PKA catalytic
subunit (New England Biolabs) in a buffer containing 20 mM Tris, pH
7.5, 10 mM MgCl2, and 25 mM ATP (2 mCi of [g-
32P]ATP). Following
phosphorylation, the peptides were digested with trypsin (0.2 mg) in 0.1
M NH4HCO3, pH 8.5, and acidified with trifluoroacetic acid, and the
radioactive peptides were purified by reverse high pressure liquid chro-
matography on a Vydac C18 (4.6 3 100-mm) column with a linear
gradient of 0–60% acetonitrile in 0.1% trifluoroacetic acid. The amount
of Raf peptide phosphorylation was determined by volume analysis of
densitometric scans (ImageQuant, Molecular Dynamics, Inc., Sunny-
vale, CA).
Immunoprecipitations and Immunoblotting—For immunoprecipita-
tion, 1 mg of cell lysate was incubated with antibody (a-FLAG or a-Raf)
for 2 h at 4 °C. 20 ml of protein A/G-agarose beads were then added and
incubated for an additional 1 h at 4 °C. Immune complexes were pel-
leted by centrifugation (12,000 3 g for 1 min), washed three times in
lysis buffer, and boiled in SDS-PAGE sample buffer. The resulting
supernatants were separated by SDS-PAGE, transferred to Immobilon
membrane (Millipore Corp.), and incubated with appropriate antibod-
ies. Immunoblots were visualized by ECL according to the manufactur-
er’s instructions (NEN Life Science Products).
Phosphorylation of Raf with PKA in Vitro—Raf was immunoprecipi-
tated and incubated with the purified, active catalytic subunit of PKA
(New England Biolabs) in the presence of [g-32P]ATP and Mg21 as
described above. Immunoprecipitates were washed with 13 PBS, and
Raf kinase was then assayed for activity as described above or analyzed
for incorporation of 32P by SDS-PAGE, autoradiography, and scintilla-
tion counting of the radioactive Raf protein. When immunoprecipitated
from baculovirus, the amount of Raf protein was estimated by Coomas-
sie staining and comparison with known amounts of bovine serum
albumin (0–25 mg) applied to the same SDS-PAGE.
RESULTS
Expression and Phosphorylation of Wild Type and Mutant
Raf Kinases in HEK 293 Cells—c-Raf (Raf) contains an optimal
consensus PKA phosphorylation site (RRAS) at Ser43 and is
phosphorylated on this amino acid in vivo (22, 26). To investi-
gate the importance of Ser43 phosphorylation in mediating the
inhibition of Raf by cAMP, the phosphorylation and regulation
of a Raf mutant protein containing an alanine substitution at
this position (S43A) was examined. HEK 293 (HEK) cells were
transiently transfected with the cDNA for WT or S43A Raf
containing a FLAG epitope tag. The WT and S43A Raf proteins
were expressed at similar levels as determined by Western
blotting of cell lysates for the FLAG epitope tag (data not
shown). HEK cells were metabolically labeled with
[32P]orthophosphate, and the phosphorylation of the WT and
S43A Raf proteins was examined by two-dimensional tryptic
phosphopeptide mapping (45). From untreated WT or S43A Raf
cells, two major phosphopeptides (I, II) were obtained after
tryptic digestion of Raf (Fig. 1, A–D). One of these peptides (II),
co-migrated with a synthetic peptide corresponding to the tryp-
tic peptide containing the Ser621 autophosphorylation site as
described earlier (26) (5) (see upper right-hand corner of Fig.
1E). Treatment of HEK cells with forskolin to increase intra-
cellular cAMP resulted in the appearance of an additional
phosphorylated peptide (III) in the WT Raf protein (Fig. 1B).
This phosphopeptide (III) co-migrated with a synthetic tryptic
peptide corresponding to the serine 43 phosphorylation site
(RASDDGK) (Fig. 1E) and was not observed in tryptic digests
of untreated WT Raf (Fig. 1A). This phosphopeptide was also
absent from tryptic digests of the S43A Raf after forskolin
treatment, thus demonstrating the absence of this phosphoryl-
ation site in vivo (Fig. 1, C and D). Relative to the peptide (I)
that was constitutively phosphorylated (see legend to Fig. 1),
forskolin did not increase the phosphorylation of the Ser621
peptide (II) or significantly change the phosphorylation of other
peptides in Raf (Fig. 1, B and D). Thus, these results confirm
that Ser43 is the major forskolin-stimulated phosphorylation
site in Raf.
Regulation of Wild Type and S43A Raf by EGF and cAMP—
The regulation of the WT and S43A Raf kinases expressed in
HEK cells was compared. HEK cells expressing either the WT
or S43A Raf were serum-deprived, and the WT or S43 Raf
proteins were immunoprecipitated with antibodies to the
epitope tag (FLAG) and immunoblotted (Fig. 2A) or assayed for
Raf kinase activity (Fig. 2B) as described under “Experimental
Procedures.” As shown in Fig. 2A, similar amounts of both WT
and S43A Raf were immunoprecipitated from equivalent
amounts of HEK cell lysates. The addition of EGF to serum-
starved HEK cells resulted in approximately a 10–15-fold in-
crease in both the WT Raf or S43A Raf kinase activities (Fig.
FIG. 1. Phosphopeptide mapping of WT and S43A Raf kinases.
HEK 293 cells expressing WT Raf (A and B) or S43A Raf (C and D) were
labeled with [32P]orthophosphate and incubated with carrier (A and C)
or with 25 mM forskolin (B and D), and the Raf proteins were immuno-
precipitated using anti-FLAG antibody. After SDS-PAGE isolation of
the phosphorylated Raf, “in gel” trypsin digestion was performed, and
the Raf peptides were analyzed by two-dimensional phosphopeptide
analysis and autoradiography. E, synthetic peptides containing the
serine 43 and serine 621 residues were phosphorylated with PKA and
[g-32P]ATP as described under “Experimental Procedures,” digested
with trypsin, and similarly analyzed. The x axis represents separation
by electrophoresis; the y axis represents separation by chromatography
as described earlier (45). The amount of peptide phosphorylation was
compared by volume analysis of densitometric scans. Peptide I, WT
without forskolin, not determined; WT plus forskolin, 111.7; S43A with-
out forskolin, 90.5; S43A plus forskolin, 94.5. Peptide II, WT without
forskolin, 85.7; WT plus forskolin, 78.9; S43A without forskolin, 66.5;
S43A plus forskolin, 65.5. Peptide III, WT without forskolin, 14.3; WT
plus forskolin, 198.9; S43A without forskolin, 16.2; S43A plus forskolin,
12.1.
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2B). In parallel with an increase in Raf activity, the migration
of both the WT and S43A Raf proteins decreased slightly on
SDS-PAGE (Fig. 2A). The time course and extent of activation
of the WT and S43A Raf kinases by EGF was indistinguishable;
the peak of Raf activity typically occurred after 5 min of EGF
addition and rapidly declined to basal levels thereafter (data
not shown).
The effect of increasing intracellular cAMP on the activity of
the WT and S43A Raf kinases was determined. Acute forskolin
treatment (5–10 min) resulted in greater than 90% inhibition of
the EGF-stimulated Raf kinase activity in HEK cells express-
ing WT Raf (Fig. 2B). Forskolin treatment also inhibited the
activation of the S43A Raf kinase to an equivalent extent.
Concomitant with the inhibition of Raf activity, the EGF-stim-
ulated shift on SDS-PAGE was abolished (Fig. 2B). The influ-
ence of forskolin was independent of the length of exposure to
EGF; hence, forskolin treatment did not simply delay the acti-
vation of Raf (data not shown). These results indicated that
phosphorylation of Ser43 was unnecessary for inhibition by
cAMP. However, to further confirm this, we compared the
regulation of a Raf kinase mutant lacking amino acids 5–50
(D5–50 Raf) and the entire consensus PKA phosphorylation
site. The D5–50 Raf was expressed in HEK cells and treated
with EGF as described above. Immunoprecipitation and immu-
noblotting of lysates for this protein demonstrated that the
D5–50 Raf protein migrated faster on SDS-PAGE, consistent
with its lower molecular weight (Fig. 2A). EGF treatment of
HEK cells resulted in approximately a 10–15-fold activation of
the D5–50 Raf kinase, similar to that observed with the WT or
the S43A Raf kinases (Fig. 2B). Like the results obtained with
the WT and S43A Raf, forskolin treatment inhibited the EGF-
dependent activation of the D5–50 Raf kinase and the EGF-
stimulated shift in migration on SDS-PAGE (Fig. 2A). Thus,
these results unequivocally demonstrate that phosphorylation
of Ser43 is not required for the inhibition of Raf by cAMP in
vivo.
PKA Phosphorylation Does Not Inhibit c-Raf Kinase Activity
in Vitro—Earlier studies proposed that Raf could be directly
inhibited by PKA phosphorylation in vitro (27, 28). Since our
studies suggested that phosphorylation of Ser43 was unneces-
sary for inhibition of Raf in vivo, we tested whether phospho-
rylation by PKA resulted in the inhibition of Raf kinase activity
in vitro. Active Raf kinase was obtained from Sf9 cells co-
infected with Raf and Src baculovirus as shown earlier (7).
Incubation of active Raf with the catalytic subunit of PKA and
Mg-ATP resulted in a time-dependent increase in the phospho-
rylation of this protein (Fig. 3A). However, despite stoichiomet-
ric phosphorylation (;0.5–1.0 mol/mol) of Raf by PKA in vitro,
no detectable loss of Raf kinase activity was observed in these
samples (Fig. 3B). Because the Src-activated Raf kinase may be
mechanistically different from Raf obtained from EGF-treated
cells, we compared the ability of PKA to inhibit the activity of
either the WT or the S43A Raf kinases immunoprecipitated
from HEK cells. Incubation of Raf from serum-starved or EGF-
stimulated cells with PKA resulted in phosphorylation of the
WT enzyme as expected (data not shown). Again, neither the
WT nor S43A Raf kinase activity was inhibited by incubation
with PKA under these conditions (Fig. 3, C and D). Hence,
these results indicate that PKA does not directly phosphorylate
and inhibit the catalytic activity of Raf in vitro.
PKA Does Not Inhibit the Activity of the Catalytic Domain of
Raf Expressed in NIH 3T3 Cells (Raf 22W) or Raf-CAAX—To
further determine the effect of PKA on Raf, we examined the
regulation of the catalytic domain of Raf kinase expressed in
vivo. Raf kinase was immunoprecipitated from NIH 3T3 cells
stably transfected with vector (pZip) or a cDNA encoding a
constitutively activated Raf protein (Raf 22W, amino acids
305–648). This constitutive activity is due to relief of N-termi-
nal autoinhibition (12), and the Raf 22W cells contained a high
level of Raf activity in the absence of serum as reported earlier
(14, 46). Incubation of the serum-starved Raf 22W cells with
forskolin only slightly inhibited the Raf kinase activity in these
cells (Fig. 4). In contrast, forskolin completely inhibited the
EGF-dependent activation of the endogenous Raf in the vector
control NIH 3T3 (pZip) cells as expected (data not shown).
Therefore, the catalytic subunit of Raf itself appears to be
resistant to inhibition by cAMP in vivo.
Because earlier studies suggested that PKA phosphorylation
of Raf on Ser43 decreased Raf/Ras association (22), we deter-
mined the influence of PKA on a Raf mutant that did not
require Ras binding for activity. The addition of a farnesyl
group to Raf (Raf-CAAX) artificially targets Raf to the plasma
membrane; this has been proposed to mimic Ras binding and
results in a constitutively active Raf kinase, ultimately result-
ing in increased cell transformation (47, 48). HEK cells were
transiently transfected with a hemagglutinin (HA)-tagged Raf-
CAAX or wild type HA-tagged Raf, and the Raf kinases were
immunoprecipitated (a-HA tag) and assayed for Raf kinase
activity. As expected, Raf-CAAX was constitutively active in
the absence of EGF treatment (Fig. 5). EGF treatment did not
increase the activity of this kinase, suggesting that Raf-CAAX
was already fully activated in these cells. However, a HA-
tagged WT Raf was activated by EGF to a similar extent as that
found with the FLAG-tagged Raf kinases as described above
(compare with Fig. 2). The effect of forskolin treatment on the
Raf kinases in these cells was compared. As shown in Fig. 5,
forskolin resulted in almost a complete inhibition of the WT Raf
FIG. 2. Regulation of the WT, S43A, and D5–50 Raf by EGF and
forskolin in HEK cells. HEK 293 cells expressing vector alone, WT
Raf, S43A Raf, and D5–50 Raf were serum-starved, incubated with 40
ng/ml EGF (5 min), or pretreated with 25 mM forskolin (10 min) prior to
EGF addition. The cells were lysed, and the Raf immunoprecipitates
(anti-FLAG) were immunoblotted for Raf (Santa Cruz C12) (A) or as-
sayed for Raf activity as described under “Experimental Procedures”
(B). In the immunoblotting experiments, the upper band represented
Raf (marked with an arrow), whereas the lower band was a contami-
nant found in all samples and was independent of Raf transfection. Raf
activity is reported in pmol/min/ml, and the results represent the
mean 6 S.E. of duplicate samples. Shown is a representative figure of
three experiments.
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but was without effect on the activity of the Raf-CAAX kinase.
Regulation of B- and c-Raf by cAMP in Liver Epithelial
Cells—Since our results suggested that PKA was not inhibiting
c-Raf directly, we compared the effects of cAMP on a related
Raf isoform, B-Raf. Although highly homologous to c-Raf
throughout the catalytic domain, B-Raf has a longer N-termi-
nal region and lacks an analogous phosphorylation site to ser-
ine 43 in c-Raf (35). Rat liver epithelial cells (GN4) express both
B- and c-Raf as demonstrated by immunoblotting for these
enzymes (data not shown). Using polyclonal antibodies specific
for each isoform, we immunoprecipitated B- and c-Raf from
serum-starved or EGF-treated GN4 cells and measured Raf
kinase activity as described above. In serum-starved cells, B-
Raf had considerably higher basal kinase activity than that
found with c-Raf (Fig. 6). As expected, EGF stimulated an
increase in the kinase activity of both enzymes; however, c-Raf
activity was increased to a greater extent than B-Raf. Treat-
ment of GN4 cells with forskolin almost completely inhibited
the EGF-stimulated c-Raf kinase and B-Raf kinase activity. In
contrast, forskolin did not effect the basal activity of either c- or
B-Raf, suggesting that only the EGF-dependent activation was
subject to regulation by this treatment (Fig. 6). Forskolin treat-
ment alone did not increase the activity of B-Raf in these cells
(data not shown). Thus, these results demonstrate that cAMP
prevents the activation of two distinct Raf isoforms in GN4
cells.
FIG. 3. PKA phosphorylates but does not inhibit the catalytic
activity of Raf in vitro. A, Raf immunoprecipitated from Sf9 cell
lysates was incubated in a buffer containing Mg21 and [g-32P] ATP with
or without the addition of the purified catalytic subunit of PKA for the
amount of time indicated. The incubated Raf samples were divided in
half and assayed for phosphorylation (A) or Raf kinase activity (B). For
phosphorylation analysis, Raf was applied to SDS-PAGE, the phospho-
FIG. 4. The catalytic domain of Raf expressed in NIH 3T3 cells
is not inhibited by cAMP. NIH 3T3 cells stably transfected with
vector (pZip) or Raf 22W were serum-starved and treated with or
without forskolin (25 mM, 30 min), Raf was immunoprecipitated from
cell lysates and assayed for kinase activity. The activity is plotted as
pmol/min/ml and represents the mean 6 S.E. of duplicate samples.
rylated Raf protein was identified by autoradiography and excised, and
the amount of radioactivity was quantitated in a liquid scintillation
counter. B, for Raf kinase activity, PKA phosphorylation was first
terminated with the addition of 100 mM PKI inhibitor peptide, and Raf
kinase activity was then measured using the coupled enzyme assay
described under “Experimental Procedures.” Results are reported as
pmol/min/ml. C and D, HEK 293 cells expressing WT (C) or S43A (D)
Raf were serum-starved and left untreated as controls or incubated
with 40 ng/ml of EGF for 5 min. Cells were harvested, and Raf was
immunoprecipitated with anti-FLAG antibody, and the immunoprecipi-
tates were incubated with 4 or 0.4 units of PKA activity and analyzed
for activity as described in B. Raf activity is reported as pmol/min/ml
and represents the mean 6 S.E. of duplicate samples. Shown are
representative results of three experiments.
Ser43 Phosphorylation Not Required for Raf Inhibition by PKA28692
DISCUSSION
Inhibition of the MAPK cascade by cAMP and the consequen-
tial activation of PKA is a widely observed phenomenon in
many different cell types (19). However, despite this observa-
tion, the mechanism by which this occurs is poorly understood
and remains controversial. Of particular interest is whether
phosphorylation of Raf is required to explain the inhibition of
this kinase in vivo. Previous studies have suggested that phos-
phorylation of Ser43 is required for Raf inhibition (22, 49);
however, a direct test of this hypothesis has not been performed
in vivo. By examining two different mutants of Raf (S43A or
D5–50 Raf), our studies now clearly demonstrate that deletion
of this region of Raf is dispensable for normal activation by
EGF or for inhibition by cAMP. This is consistent with studies
showing that the primary Ras binding domain of Raf includes
amino acids 51–131 (see Ref. 12 and references therein) and
would imply that Ser43 is outside the region required for Raf/
Ras binding in vivo. These conclusions are further supported by
our findings with B-Raf showing that cAMP inhibits activation
of a related isoform lacking an analogous Ser43 phosphoryla-
tion site. Although our phosphopeptide mapping results con-
firm that Ser43 is the major site of cAMP-stimulated phospho-
rylation in c-Raf in vivo (26), the finding that removing Ser43
does not affect Raf regulation indicates that phosphorylation of
this site remains an enigma.
Previously it was suggested that phosphorylation of Raf on
Ser621 was responsible for inhibition of c-Raf kinase in vivo
(28). Although the authors demonstrated that PKA phospho-
rylated Raf on Ser621 in vitro, evidence for the forskolin or
cAMP-stimulated phosphorylation of Ser621 in vivo was not
presented. In our phosphopeptide mapping studies, we ob-
served two constitutively phosphorylated peptides in Raf, one
of which co-migrated with the synthetic Ser621 tryptic peptide,
whereas the other most likely corresponds to the Ser259 auto-
phosphorylation peptide as shown earlier (26). We found no
evidence for increased phosphorylation of Ser621 in response to
forskolin treatment of cells. Instead, this peptide was phospho-
rylated equally in both untreated and forskolin-treated cells,
consistent with this amino acid being a major autophosphoryl-
ation site in vivo (26) and arguing against Ser621 as a valid PKA
phosphorylation site in vivo. In addition, compared with the
Ser43 peptide, the Ser621 peptide lacks the optimal pair of basic
residues (RSAS) and is a poor substrate for PKA in vitro.
Phosphorylation of the Ser621 peptide occurred at a rate ap-
proximately 100 times lower than that observed with the Ser43
peptide in vitro.2 Instead, Ser621 is efficiently phosphorylated
by the AMP-activated protein kinase (50). In other studies,
phosphorylation of Ser621 has been shown to be required for
both 14-3-3 binding and Raf activity (5). Hence, it seems un-
likely that a phosphorylation site that is essential for Raf
activity would also be required for inhibition as suggested by
Kolch and co-workers (28). These observations combined with
our in vivo phosphopeptide mapping studies strongly suggest
that phosphorylation of Ser621 does not mediate the cAMP-de-
pendent inhibition of Raf kinase in vivo.
Although our data demonstrated that phosphorylation of
Ser43 was not required for the inhibition of Raf kinase in vivo,
PKA might still prevent Raf/Ras association at the plasma
membrane as suggested earlier (22). Our experiments with
Raf-CAAX were designed to test this hypothesis, and, consist-
ent with this model, we find that this protein is completely
resistant to inhibition by cAMP. Although these results may
argue that the primary effect of PKA is to disrupt Ras/Raf
association, there are other potential interpretations of these
results. For instance, once activated, Raf may be resistant to
the effects of PKA. Our results with the PKA phosphorylation
of active Raf in vitro or forskolin treatment of the Raf 22W cells
would support this model. Using either the baculovirus-ex-
pressed Raf, the EGF-activated WT, or S43A Raf from HEK
cells, the truncated and active form of Raf expressed in NIH
3T3 cells or Raf-CAAX, we found no evidence for the direct
inhibition of Raf kinase by PKA either in vitro or in vivo. In this
regard, our results are in agreement with the studies of White-
hurst et al. (51), suggesting that the catalytic subunit of c-Raf
is not directly inhibited by PKA.
Instead, our findings would be consistent with cAMP inhib-
iting an event required for the activation of both B- and c-Raf.
This hypothesis would be in agreement with earlier studies
showing that cAMP inhibited the Ras-dependent activation of
B-Raf (29, 30) and would be supported by our results demon-
2 M. Sidovar, unpublished observations.
FIG. 5. Forskolin treatment does not affect Raf-CAAX activity.
HEK 293 cells expressing vector, HA-tagged WT Raf, or HA-tagged
Raf-CAAX were serum-starved for 24 h. Cells were then left untreated
as controls, treated with EGF (40 ng/ml, 5 min), or treated with fors-
kolin (25 mM, 10 min) followed by EGF (5 min). Cells were lysed, Raf was
immunoprecipitated with anti-HA antibody, and the Raf activity was
determined. Raf activity is reported as pmol/min/ml and represents the
mean 6 S.E. of duplicate samples. Shown is a representative figure of
three experiments.
FIG. 6. Forskolin prevents the activation of B- and c-Raf in
GN4 epithelial cells. Rat liver GN4 epithelial cells were serum-
starved (18 h) and incubated with carrier (Me2SO) or forskolin (25 mM,
10 min), prior to treatment with EGF (40 ng/ml, 5 min). The cells were
collected in cell lysis buffer, and the B- and c-Raf kinases were immu-
noprecipitated and assayed for Raf kinase activity as described earlier.
The results represent the mean 6 S.E. of duplicate samples. Shown is
a representative figure of two experiments.
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strating that forskolin prevents the EGF-dependent activation
of both B- and c-Raf in GN4 cells. The lack of effect of forskolin
on the basal activity of either B- or c-Raf in GN4 cells reiterates
our findings showing that PKA does not directly inhibit the
catalytic activity of Raf. Because the catalytic regions of both
B-Raf and c-Raf are highly homologous (35) and because other
recent studies have found that B-Raf is resistant to inhibition
by PKA (32), we believe argues against a direct effect of PKA on
the catalytic domain of Raf. Although these authors (32) did see
a partial inhibitory effect of PKA on c-Raf (less than 50%), we
do not believe that this incomplete effect accounts for the
greater than 90% inhibition of c-Raf activity that we observed
in vivo.
Additional targets that were not investigated in this study
include the Rap proteins. Although these proteins are phospho-
rylated by PKA in vivo (37) and can physically antagonize the
binding of c-Raf to Ras (52), the most recent studies suggest
that PKA phosphorylation may diminish the inhibitory poten-
tial of these proteins (53). Furthermore, considerable evidence
suggests that cAMP-dependent activation of Rap results in the
activation of B-Raf (43) (31). Although we did not observe a
stimulatory effect of cAMP on B-Raf in the GN4 cells,3 this may
be explained by cell type differences in the expression of Rap as
described by others (34). Thus, these findings, combined with
the recent studies showing that Rap is not required for the
inhibition of MAPK signaling (40), suggest that Rap proteins do
not mediate the inhibition of Raf observed in our studies.
So what might explain the inhibitory effects of cAMP on Raf?
Recent studies have shown that PAK3 can function as a Raf
kinase, thus contributing to the activation of Raf by growth
factors and other stimuli (10, 54). Interestingly, studies from
Howe et al.4 show that PAK contains a consensus PKA phos-
phorylation site and find that PAK is phosphorylated and in-
hibited in response to forskolin treatment of cells. This obser-
vation would be consistent with our findings suggesting that
PKA phosphorylation of Raf itself is insufficient to explain the
inhibition observed in vivo; however, whether or not the phos-
phorylation of PAK by PKA is required to account for this
regulation remains to be established.
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